Blue Trust Inc. increased its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 36.3% during the ...

Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc ...

Cantor Fitzgerald upgraded shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) from a neutral rating to an overweight rating in a research note published on Wednesday morning, Marketbeat reports.

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

Check the time stamp on this data. Updated AI-Generated Signals for Beam Therapeutics Inc. (BEAM) available here: BEAM. Type ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and ...

In the preceding three months, 4 analysts have released ratings for Beam Therapeutics BEAM, presenting a wide array of perspectives from bullish to bearish. The following table summarizes their ...

The average of price targets set by Wall Street analysts indicates a potential upside of 84.5% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, ...